Methadone maintenance dosing guideline for opioid dependence, a literature review

Journal of Addictive Diseases

Volumn 29, Issue 1, 2010, Pages 1-14

  Fareed, Ayman ^a,b   Casarella, Jennifer ^a   Amar, Richard ^a   Vayalapalli, Sreedevi ^a   Drexler, Karen ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Doing guideline; Literature review; Methadone

Indexed keywords

AMFEBUTAMONE; BUPRENORPHINE; ILLICIT DRUG; METHADONE; OPIATE; NARCOTIC AGENT;

CLINICAL TRIAL; DRUG DETOXIFICATION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG TRAFFIC; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MEDLINE; METHADONE TREATMENT; MORTALITY; OPIATE ADDICTION; OUTCOME ASSESSMENT; REVIEW; DOSE RESPONSE; DRUG ADMINISTRATION; OBSERVATION; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; METHADONE; NARCOTICS; OBSERVATION; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77951251693     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550880903436010     Document Type: Review

References (65)

1. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 1965; 193:80-84
2. Dole VP, Nyswander ME. Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med 1966; 66:2011-2017
3. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services and outcome. New York: Springer-Verlag, 1991.
4. Eissenberg T, Bigelow GE, Strain EC, Walsh SL, Brooner RK, Stitzer ML, Johnson RE. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: a randomized clinical trial. JAMA 1997; 277:1945-1951 (Pubitemid 27272772)
5. Ling W, Charuvastra VC, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts: a Veterans Administration cooperative study. Arch Gen Psychiatry 1976; 33:709-720
6. Marsch LA. The efficacy ofmethadone maintenance interventions in reducing illicit opiate use, HIV risk behavior, and criminality: a meta-analysis. Addiction 1998; 93:515-532
7. Maddux JF, EsquivelM, Vogtsberger KN, Desmond DP. Methadone dose and urine morphine. J Subst Abuse Treat. 1991; 8:195-201.
8. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, de Olalla G, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005; 100:981-989 (Pubitemid 40897293)
9. Rathod NH, Addenbrooke WM, Rosenbach AF. Heroin dependence in an English town: 33-year follow-up. Br J Psychiatry 2005; 187:421-425
10. Sorensen HJ, Jepsen PW, Haastrup S, Juel K. Druguse pattern, comorbid psychosis and mortality in people with a history of opioid addiction. Acta Psychiatr Scand 2005; 111:244-249 (Pubitemid 40342193)
11. Termorshuizen F, Krol A, Prins M, Geskus R, van den Brink W, van Ameijden EJ. Long-term outcome of chronic drug use: the AmsterdamCohort Study among drug users. Am J Epidemiol 2005: 161:271-279 (Pubitemid 40223515)
12. De Angelis D, Hickman M, Yang SY. Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol 2004; 160:994-1004. (Pubitemid 39488428)
13. Vlahov D, Wang CL, Galai N, Bareta J, Mehta SH, Strathdee SA, Nelson KE. Mortality risk among new onset injection drug users. Addiction 2004; 99:946-954 (Pubitemid 39452806)
14. Oppenheimer E, Tobutt C, Taylor C, Andrew T. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction 1994; 89:1299-1308 (Pubitemid 24310621)
15. Barr HL, Antes D, Ottenberg DJ, Rosen A. Mortality of treated alcoholics and drug addicts: the benefits of abstinence. J Stud Alcohol 1984; 45:440-452 (Pubitemid 14024938)
16. Haastrup S, Jepsen PW. Seven year follow-up of 300 young opioid addicts. Acta Psychiatr Scand 1988; 77:503-509 (Pubitemid 18046348)
17. Joe GW, Lehman W, Simpson DD. Addict death rates during a four-year posttreatment follow-up.AmJ Publ Health 1982; 72:703-709
18. Joe GW, Simpson DD. Mortality rates among opioid addicts in a longitudinal study. Am J Publ Health 1987; 77:347-348
19. SmythB,HoffmanV, Fan J,HserY-I.Years of potential life lost among heroin addicts 33 years after treatment. Prev Med 2007; 44:369-374 (Pubitemid 46550676)
20. Alterman AL,Rutherford MJ,Cacciola JS,McKaym JR, Boardman CR. Prediction of 7 months methadone maintenance treatment response by four measures of antisociality. Drug Alcohol Depend 1998; 49:217-223
21. McLellan AT. Patient characteristics associated with outcome. In: Cooper JR, Altman F, Brown BS, Czechowicz D, eds. Research on the treatment of drug addiction: state of the art (NIDA Research Monograph Series Publication No. ADM 83-1281). Washington, DC: U.S. Government Printing Office, 1983.
22. McLellan AT, Luborsky L, Woody GE, O'Brien CP, Druley KA. Predicting response to drug and alcohol treatment: role of psychiatric severity. Arch Gen Psychiatry 1983: 40:620-625 (Pubitemid 13094929)
23. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994; 154:1121-1127 (Pubitemid 24155211)
24. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167:2469-2475
25. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290-1297
26. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998; 88:34-39 (Pubitemid 28109638)
27. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry 2000; 57:395-404. (Pubitemid 30202331)
28. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281:1000-1005 (Pubitemid 29143891)
29. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53:401-407 (Pubitemid 26149228)
30. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54:713-720 (Pubitemid 27344098)
31. Donny EC, Walsh SL, Bigelow GE, Eissenberg T, Stitzer ML.High-dosemethadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioiddependent humans. Psychopharmacology (Berl) 2002; 161:202-212 (Pubitemid 34492665)
32. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; 3, July:CD002208.
33. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA1998; 280:1936-1943.
34. Pollack HA, D'Aunno T. Dosage patterns in methadone treatment: results from a national survey, 1988-2005. Health Serv Res 2008; 43(6):2143-2163
35. Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of higher dose methadone. J Psychoactive Drugs 1999; 31:95-102. (Pubitemid 29321418)
36. Maxwell S, Shinderman MS. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dosemethadone. J Addict Dis 2002; 21:1-12. (Pubitemid 35204999)
37. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin selfadministration in opioid-dependent volunteers. Addiction 2005; 100:1496-1509
38. Banys P, Tusel DJ, Sees KL, Reilly PM, Delucchi KL. Low (40 mg) versus high (80 mg) dose methadone in a 180-day heroin detoxification program. J Subst Abuse Treat 1994; 11:225-232 (Pubitemid 24184965)
39. Brady TM, Salvucci S, Sverdlov LS, Male A, Kyeyune H, Sikali E, DeSale S, Yu P. Methadone dosage and retention: an examination of the 60 mg/day threshold. J Addict Dis 2005; 24:23-47. (Pubitemid 41548278)
40. Blaney T, Craig RJ. Methadone maintenance. Does dose determine differences in outcome? J Subst Abuse Treat 1999; 16:221-228 (Pubitemid 29133794)
41. Trafton JA, Minkel J, Humphreys K. Determining effective methadone doses for individual opioid-dependent patients. PLoS Med 2006; 3:e80.
42. Maddux JF, Prihoda TJ, Vogtsberger KN. The relationship ofmethadone dose and other variables to outcomes of methadone maintenance. Am J Addict 1997; 6:246-255
43. Farr M, Mas A, Torrens M, Moreno V, Cam J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002; 65:283-290 (Pubitemid 34159075)
44. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use.AmJ Public Health 1995; 85:83-88
45. Torrens M, Castillo C, Pérez-Sol V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend 1996; 41:55-59 (Pubitemid 26185295)
46. D'Ippoliti D, Davoli M, Perucci CA, Pasqualini F, Bargagli AM. Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend 1998; 52:167-171 (Pubitemid 28529496)
47. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine vs. methadone maintenance for opioid dependence. J Nervous Mental Disease 1993; 181:358-364 (Pubitemid 24259606)
48. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267:2750-2755
49. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Methadone dose and treatment outcome. Drug Alcohol Depend 1993; 33:105-117
50. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119:23-27 (Pubitemid 23177293)
51. Roszell DK, Calsyn DA.Methadone dosage: patient characteristics and clinical correlates. Int J Addict 1986; 21:1233-1246
52. Latowsky M. Methadone death, dosage, and torsade de pointes: risk-benefit policy implications. J Psychoactive Drugs 2006; 38:513-519 (Pubitemid 46340096)
53. Cruciani RA. Methadone: to ECG or not to ECG. . .That is still the question. J Pain Symptom Manage 2008; 36:545-552
54. Peles E, Bodner G, Kreek MJ, Rados V, AdelsonM. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 2007; 102:289-300. (Pubitemid 46096291)
55. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL. QTc interval prolongation associated with intravenous methadone. Pain 2003; 105:499-506. (Pubitemid 37186911)
56. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005; 11:44-49 (Pubitemid 40082210)
57. EhretGB,VoideC,Gex-Fabry M, Chabert J, ShahD, Broers B, Piguet V,Musset T, Gaspoz JM, Perrier A, Dayer P, Desmeules JA. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166:1280-1287 (Pubitemid 43967579)
58. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007; 93:1051-1055 (Pubitemid 47310981)
59. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, Schweitzer P, Yancovitz SR, Lapin JA, Shaiova L, Shen RG, Portenoy RK. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 2005; 29:385-391 (Pubitemid 40602519)
60. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95:915-918 (Pubitemid 40386816)
61. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003; 23:802-805 (Pubitemid 36629083)
62. Krantz MJ; Martin J, Stimmel B, Mehta D, Haigney MCP. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387-395
63. Dolophine Hydrochloride CII (Methadone Hydrochloride Tablets, USP) 5 mg, 10 mg, Rx Only. Columbus, OH: Roxane Laboratories; 2006. Accessed at www.fda.gov/cder/foi/label/2006/006134s028lbl.pdf on 12 November 2008.
64. Zanis DA,Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend 1998; 52:257-260
65. Woody GE, Kane V, Lewis K, Thompson R. Premature deaths after discharge from methadone maintenance: a replication. J Addict Med 2007; 1:180-185